Health knowledge made personal
Join this community!
› Share page:
Search posts:

New Data Shows Epratuzumab Provided Significant Efficacy for Patients with Moderate to Severe Systemic Lupus Erythematosus

Posted Jun 16 2010 12:10pm
UCB and Immunomedics Inc. announced today that a new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Findings demonstrate that in a patient population with predominantly severe disease activity, epratuzumab is improving patients' health as quickly as week 12, with the emergence of improvements as early as week 8.


Post a comment
Write a comment:

Related Searches